CD163 and breast cancer: A meta-analysis of 8,496 breast cancer patients across 32 studies found that increased CD68+ and CD163+ TAM densities are significantly associated with decreased overall survival (HR= 1.7–2.5) and shorter disease-free survival (HR=1.8) [103].